Cargando…

Modified Qing’ e Pills exerts anti-osteoporosis effects and prevents bone loss by enhancing type H blood vessel formation

OBJECTIVE: To explore whether the modified Qing’ e Pills (MQEP) exerts anti-osteoporotic effects and prevents bone loss by enhancing angiogenesis. METHODS: Network pharmacology was used to assess whether MQEP has a pro-angiogenic capacity and to predict its potential targets. Human umbilical vein en...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Junjie, Hu, Desheng, Ma, Chen, Xu, Xiaojuan, Shen, Lin, Rong, Jianhui, Zhao, Jia, Shuai, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485463/
https://www.ncbi.nlm.nih.gov/pubmed/36147560
http://dx.doi.org/10.3389/fendo.2022.998971
_version_ 1784792075877744640
author Lu, Junjie
Hu, Desheng
Ma, Chen
Xu, Xiaojuan
Shen, Lin
Rong, Jianhui
Zhao, Jia
Shuai, Bo
author_facet Lu, Junjie
Hu, Desheng
Ma, Chen
Xu, Xiaojuan
Shen, Lin
Rong, Jianhui
Zhao, Jia
Shuai, Bo
author_sort Lu, Junjie
collection PubMed
description OBJECTIVE: To explore whether the modified Qing’ e Pills (MQEP) exerts anti-osteoporotic effects and prevents bone loss by enhancing angiogenesis. METHODS: Network pharmacology was used to assess whether MQEP has a pro-angiogenic capacity and to predict its potential targets. Human umbilical vein endothelial cells were treated with glucocorticoids and MQEP to assess cell viability. The expression of angiotensin II type 1 receptor, angiotensin II type 2 receptor, and angiotensin converting enzyme, which are associated with the activation of the renin-angiotensin-aldosterone system, and the expression of vascular endothelial growth factor and hypoxia-inducible factor 1 alpha, which are associated with the formation of type H blood vessels, were examined by western blot and RT-qPCR. Thereafter, the glucocorticoid-induced osteoporosis model was established and intervened with MQEP. Femur scanning was performed with micro-computed tomography; trabecular spacing, trabecular thickness, and trabecular number were observed and calculated; the expression of nuclear factor-kappa B ligand and osteoprotegerin was detected by ELISA, and the ratio was calculated to evaluate the degree of bone resorption. Finally, type H blood vessels that were highly coupled to osteogenic cells were identified by immunohistochemistry staining and flow cytometry. RESULTS: This is the first study to reveal and confirm that MQEP could prevent bone loss in glucocorticoid-induced osteoporosis by promoting the expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor, which are highly associated with type H blood vessel formation. In vitro experiments confirmed that MQEP could effectively promote the proliferation of vascular endothelial cells and alleviate glucocorticoids-induced activation of the renin-angiotensin-aldosterone system, thereby reducing vascular injury. CONCLUSION: MQEP exerts anti-osteoporosis effects and prevents bone loss by alleviating vascular injury caused by renin-angiotensin-aldosterone system activation and promoting type H blood vessel formation.
format Online
Article
Text
id pubmed-9485463
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94854632022-09-21 Modified Qing’ e Pills exerts anti-osteoporosis effects and prevents bone loss by enhancing type H blood vessel formation Lu, Junjie Hu, Desheng Ma, Chen Xu, Xiaojuan Shen, Lin Rong, Jianhui Zhao, Jia Shuai, Bo Front Endocrinol (Lausanne) Endocrinology OBJECTIVE: To explore whether the modified Qing’ e Pills (MQEP) exerts anti-osteoporotic effects and prevents bone loss by enhancing angiogenesis. METHODS: Network pharmacology was used to assess whether MQEP has a pro-angiogenic capacity and to predict its potential targets. Human umbilical vein endothelial cells were treated with glucocorticoids and MQEP to assess cell viability. The expression of angiotensin II type 1 receptor, angiotensin II type 2 receptor, and angiotensin converting enzyme, which are associated with the activation of the renin-angiotensin-aldosterone system, and the expression of vascular endothelial growth factor and hypoxia-inducible factor 1 alpha, which are associated with the formation of type H blood vessels, were examined by western blot and RT-qPCR. Thereafter, the glucocorticoid-induced osteoporosis model was established and intervened with MQEP. Femur scanning was performed with micro-computed tomography; trabecular spacing, trabecular thickness, and trabecular number were observed and calculated; the expression of nuclear factor-kappa B ligand and osteoprotegerin was detected by ELISA, and the ratio was calculated to evaluate the degree of bone resorption. Finally, type H blood vessels that were highly coupled to osteogenic cells were identified by immunohistochemistry staining and flow cytometry. RESULTS: This is the first study to reveal and confirm that MQEP could prevent bone loss in glucocorticoid-induced osteoporosis by promoting the expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor, which are highly associated with type H blood vessel formation. In vitro experiments confirmed that MQEP could effectively promote the proliferation of vascular endothelial cells and alleviate glucocorticoids-induced activation of the renin-angiotensin-aldosterone system, thereby reducing vascular injury. CONCLUSION: MQEP exerts anti-osteoporosis effects and prevents bone loss by alleviating vascular injury caused by renin-angiotensin-aldosterone system activation and promoting type H blood vessel formation. Frontiers Media S.A. 2022-09-06 /pmc/articles/PMC9485463/ /pubmed/36147560 http://dx.doi.org/10.3389/fendo.2022.998971 Text en Copyright © 2022 Lu, Hu, Ma, Xu, Shen, Rong, Zhao and Shuai https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Lu, Junjie
Hu, Desheng
Ma, Chen
Xu, Xiaojuan
Shen, Lin
Rong, Jianhui
Zhao, Jia
Shuai, Bo
Modified Qing’ e Pills exerts anti-osteoporosis effects and prevents bone loss by enhancing type H blood vessel formation
title Modified Qing’ e Pills exerts anti-osteoporosis effects and prevents bone loss by enhancing type H blood vessel formation
title_full Modified Qing’ e Pills exerts anti-osteoporosis effects and prevents bone loss by enhancing type H blood vessel formation
title_fullStr Modified Qing’ e Pills exerts anti-osteoporosis effects and prevents bone loss by enhancing type H blood vessel formation
title_full_unstemmed Modified Qing’ e Pills exerts anti-osteoporosis effects and prevents bone loss by enhancing type H blood vessel formation
title_short Modified Qing’ e Pills exerts anti-osteoporosis effects and prevents bone loss by enhancing type H blood vessel formation
title_sort modified qing’ e pills exerts anti-osteoporosis effects and prevents bone loss by enhancing type h blood vessel formation
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485463/
https://www.ncbi.nlm.nih.gov/pubmed/36147560
http://dx.doi.org/10.3389/fendo.2022.998971
work_keys_str_mv AT lujunjie modifiedqingepillsexertsantiosteoporosiseffectsandpreventsbonelossbyenhancingtypehbloodvesselformation
AT hudesheng modifiedqingepillsexertsantiosteoporosiseffectsandpreventsbonelossbyenhancingtypehbloodvesselformation
AT machen modifiedqingepillsexertsantiosteoporosiseffectsandpreventsbonelossbyenhancingtypehbloodvesselformation
AT xuxiaojuan modifiedqingepillsexertsantiosteoporosiseffectsandpreventsbonelossbyenhancingtypehbloodvesselformation
AT shenlin modifiedqingepillsexertsantiosteoporosiseffectsandpreventsbonelossbyenhancingtypehbloodvesselformation
AT rongjianhui modifiedqingepillsexertsantiosteoporosiseffectsandpreventsbonelossbyenhancingtypehbloodvesselformation
AT zhaojia modifiedqingepillsexertsantiosteoporosiseffectsandpreventsbonelossbyenhancingtypehbloodvesselformation
AT shuaibo modifiedqingepillsexertsantiosteoporosiseffectsandpreventsbonelossbyenhancingtypehbloodvesselformation